EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation

Kevin Cyrys, Robert Zweigerdt

Advanced Drug Delivery Reviews · 2026-08 · 235 · 115904

DOI: 10.1016/j.addr.2026.115904 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-08. Verfasst von Kevin Cyrys und 1 weiteren Autor:innen. Beteiligte Einrichtung: Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic Transplantation and Vascular Surgery (HTT…. Hauptthemen laut MEDLINE: Pluripotent Stem Cells, Cell Differentiation, Cell Culture Techniques. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: REBIRTH HANNOVER Forschungszentrum für translationale regenerative Medizin, Bundesministerium für Forschung, Technologie und Raumfahrt, European Health and Digital Executive Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human pluripotent stem cells (hPSCs) can serve as an unlimited, renewable "raw material" for essentially any therapeutic cell product, placing them at an exciting intersection of biology, manufacturing and the emerging field of regenerative medicine. In the last decade, the field has progressed to the initiation of >100 clinical trials applying hPSC-derivatives for a spectrum of diseases. However, for enabling the envisioned routine hPS cell therapies in future, novel industry-scale manufacturing processes compliant with clinical and regulatory needs are required. Recently, the bioprocessing field has shifted from proof-of-concept studies demonstrating that pluripotent cells and their derivatives can be grown in suspension culture in dynamic systems, toward advanced processes that can be standardized, intensified, and successfully transferred between production sides. In this article, we provide a brief historical background on hPS cell manufacturing but will mainly focus on recent developments in the field. This includes suspension culture (3D)-based bioprocessing strategies for both the cultivation/ expansion of hPSCs at the pluripotent state and their lineage-directed differentiation as well, such as clinically relevant examples of functional cell types representative of all three germ layers. Since industrial-scale bioprocessing is more than just cell yields, aspects of volumetric productivity, production time, challenges for process reproducibility and others will be outlined. Additional aspects will include the optimization of upstream expansion and its integration with directed differentiation protocols as well as downstream handling into coherent, GMP-ready, clinically compliant production processes. Finally, an outlook is provided, indicating that bioreactor-based hPSC manufacturing in future will be defined by more controlled, data-rich, and economically defensible production processes feedback-controlled by artificial intelligence and machine learning. This will promote moving from retrospective process analytics to validated in process decision support for reducing production batch failure across individual hPSC lines, tightening comparability, and enabling more consistent product definition across production sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pluripotent Stem CellsCell DifferentiationCell Culture TechniquesHumansBioreactors

Stichwörter der Autor:innen

BioprocessCell therapy, artificial inteligenceDirected differentiationEctodermEndodermHuman pluripotent stem cells (hPSCs)ManufacturingMesodermStirred tank bioreactor (STBR)Suspension cultureVertical-wheel bioreactor (VWBR)

Autor:innen und Institutionen

  • Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Department of Cardiothoracic Transplantation and Vascular Surgery (HTTG), Hannover Medical School (MHH), Carl Neuberg-Str. 1, Hannover 30625…

Förderung

  • REBIRTH HANNOVER Forschungszentrum für translationale regenerative Medizin
  • Bundesministerium für Forschung, Technologie und Raumfahrt
  • European Health and Digital Executive Agency
  • Deutsche Forschungsgemeinschaft
  • European Commission

Zitieren

APA

Cyrys, K., & Zweigerdt, R. (2026). Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation. Advanced Drug Delivery Reviews, 235, 115904. https://doi.org/10.1016/j.addr.2026.115904

Vancouver

Cyrys K, Zweigerdt R. Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation. Advanced Drug Delivery Reviews. 2026;235:115904. doi:10.1016/j.addr.2026.115904

BibTeX
@article{Cyrys2026,
  author = {Cyrys, Kevin and Zweigerdt, Robert},
  title = {Scalable process technologies for human pluripotent stem cells (hPSCs) expansion and differentiation},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {235},
  pages = {115904},
  doi = {10.1016/j.addr.2026.115904}
}
Kostenlos starten →